Ovarian Cancer Research Alliance is dedicated to fostering an environment that provides the best possible healthcare and support for those with ovarian cancer and those who could be at risk.
As the only national organization dedicated to fighting for ovarian cancer issues on Capitol Hill, we take our duty to protect the patient community very seriously. From working to enhance the public investment in ovarian cancer research and education, to ensuring that patients are protected with adequate safety regulations and coverage, OCRA works to always represent our patient community.
But we can’t do this important work without people like you! Here are a few ways you can help amplify your voice and help ovarian cancer patients everywhere:
Your elected officials need to hear from YOU to ensure that ovarian cancer research and education programs remain a congressional priority. We bring together survivors, caregivers and supporters to advocate virtually for programs and research that pave the way for better treatments for ovarian cancer. Sign up to be notified when registration is open.
Learn about our policy positions.
These policies help protect patients, educate the general population and ensure that every patient receives the best care available.
Become an Advocate Leader.
We train top advocates to speak up in their communities and represent our cause with their elected officials.
Become an e-advocate.
You will receive important Action Alerts and learn how to communicate with with your elected officials.
Become a Research Advocate.
Research Advocates help funding agencies and scientists understand and prioritize the questions that are important to the ovarian cancer community.
OCRA is honored to receive the 5th Annual Gabriella Graham Patient Advocacy Award from the Society of Surgical Oncology. This award is presented annually to an individual or patient advocacy organization that has provided support and hope to patients and families facing cancers that are often treated with a regional treatment approach, such as intraperitoneal chemotherapy.